Skip to content

    Insecticid.India

    INSECTICID
    Chemicals·12 Nov 2025
    Management Summary

    Insecticides (India) Limited reported a resilient Q2 FY26 with a 2% revenue growth to ₹638 crores and an 11% gross profit increase, despite adverse weather conditions impacting the agrochemical market. The company launched five new products and maintained a focus on specialty products, contributing to a 13% H1 EBITDA margin. However, PAT declined 3.3% due to higher financial costs and increased goods returns, leading to an inventory build-up.

    Highlights

    5

    • Revenue of ₹638 crores, up 2% YoY, demonstrating resilience in a tough market.

    • Gross profit increased 11% YoY to ₹220 crores, driven by product mix.

    • Successfully launched five new products, including patented Altair and Sparcle, enhancing portfolio.

    • H1 EBITDA margin maintained at 13%, indicating focus on profitable growth.

    • Intensified field promotion activities and digitization led to better sales performance compared to peers.

    Concerns

    4

    • PAT declined 3.3% YoY to ₹59 crores due to higher financial costs and slow debtor recovery.

    • Goods return increased 50% YoY to ₹150 crores, reflecting market challenges.

    • Inventory levels crossed ₹700 crores against a target of ₹600 crores, potentially tying up working capital.

    • Subdued agrochemical demand in the domestic market due to adverse weather conditions.

    What Changed1

    vs Q3 FY26

    Guidance items8 → 6 (-2)

    Key financials

    Single quarter

    08 metrics
    1. 01Revenue from Operations₹638 Cr+2%YoY
    2. 02Gross Profit₹220 Cr+11%YoY
    3. 03EBITDA₹89 Cr-1.1%YoY
    4. 04PAT₹59 Cr-3.3%YoY
    5. 05H1 EBITDA Margin13%

    Capital allocation

    3
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    Maintain working capital and cash flow focus.

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    FY26 Revenue Growth
    double-digit growth
    		Medium
    Product Portfolio
    Own Technicals Contribution to FM Range
    crossing 70%
    		High
    Product Launches
    New ALS Launches in Technical Segment
    3-4 new Als at least
    		High
    Profitability
    New Product Margins (Maharatna Segment)
    35% plus
    		High
    Sales
    Kaeros Sales Contribution
    ₹100 crore
    		High
    Order Book
    Export Order Book Completion
    complete
    		High

    FY26 Revenue Growth Recovery

    FY26
    Current4% in H1 FY26
    TargetDouble-digit growth for FY26

    Why it matters

    Indicates the company's ability to recover from H1 challenges and achieve its annual growth targets, crucial for overall performance.

    I still maintain that target because I believe my expectation from my ST is good. So, we should be able to make the recovery. If you look at first half, we have grown by almost 4%. So, I have to make that recovery. I should be able to do that to a larger extent. So, we should be very near to what targets we have kept for this year.

    How to verify

    key_financials.metrics[label='Revenue']

    Risks & concerns

    5
    RiskSeverity

    Challenging monsoon and adverse weather conditions

    Heavy rains and dry spells disrupted agronomic activities, causing crop damage, delayed harvest, and subdued agrochemical demand in the domestic market. — Management acknowledged

    high

    Increased goods returns

    Goods returns increased by 50% YoY to ₹150 crores, indicating market challenges and impacting sales. — Management acknowledged

    medium

    Inventory build-up

    Inventory levels rose to ₹700 crores, exceeding the target of ₹600 crores, potentially tying up working capital, though management views it as necessary for the new season. — Management acknowledged

    medium

    Increased competition for off-patented molecules

    Competition for off-patented products now emerges within 6 months, shortening the window for competitive advantage and requiring continuous innovation. — Management acknowledged

    medium

    Loss of yield in Kharif season

    Farmers experienced significant yield losses in maximum crops during the Kharif season, impacting their income and sentiment. — Management acknowledged

    high

    Q&A highlights

    8

    “There is technically no volume growth in the FM and Maharatna segment. Might be a small percentage. So, not big.”

    Reveals flat volume growth in key premium segments, suggesting revenue growth was driven by price/mix or other segments.

    asked by Bharat Gupta

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 FY26 Performance Amidst Challenging Monsoon

    Insecticides (India) Limited reported a 2% year-on-year revenue increase to ₹638 crores for Q2 FY26, up from ₹627 crores in Q2 FY25, demonstrating resilience despite a challenging monsoon season. Gross profit saw an 11% growth, rising from ₹199 crores to ₹220 crores. However, EBITDA slightly declined from ₹90 crores to ₹89 crores, and PAT decreased by 3.3% from ₹61 crores to ₹59 crores, primarily due to higher financial costs and slower debtor recovery.

    02

    Strategic Product Launches and Portfolio Premiumization

    The company successfully launched five new products in Q2 FY26, including patented offerings like Altair (pre-emergent herbicide) and Sparcle (broad-spectrum insecticide), along with Amuse, Centran SC, and Brahmos. Management emphasized a strategic shift towards a specialty portfolio, with own technicals and partner technicals now contributing 65% to the Focus Maharatna range, targeting over 70% in the next 2-3 years. This premiumization strategy aims for 35%+ margins on new products.

    03

    Market Headwinds and Inventory Management

    The monsoon season was characterized by initial positive signs followed by heavy rains and dry spells, disrupting agronomic activities, causing crop damage, and leading to subdued agrochemical demand. This resulted in a 50% increase in goods returns, reaching ₹150 crores compared to ₹100 crores last year. Inventory levels rose to ₹700 crores, exceeding the target of ₹600 crores, which management attributed to building necessary stock for the upcoming Rabi season.

    04

    Enhanced Market Engagement and Operational Leadership

    To navigate market challenges🌐, the company intensified its field promotion activities, increasing the number of crop advisors from 750-800 to 1,500 during peak season, currently maintaining 1,200. These efforts, coupled with digitization and a focus on specialty products, helped the company achieve better sales compared to peers. The appointment of Mr. Devendra Ray as COO is expected to professionalize and scale manufacturing, expansion, and supply chain management.

    05

    Outlook for Rabi Season and FY26 Targets

    Despite the Kharif season's challenges, management expressed cautious optimism for the Rabi season, citing adequate soil moisture from extended rainfall and anticipating increased wheat and pulse sowing. They expect a better-than-usual H2 performance, crucial for offsetting Kharif losses. The company maintains its target for double-digit revenue growth for FY26 and aims for ₹100 crores contribution from its new product, Kaeros, by year-end, having achieved ₹70 crores gross sales in H1.

    06

    Continuous Innovation and Backward Integration

    The company is committed to continuous innovation and backward integration, developing technologies from basic stages to enhance competitiveness. Management acknowledged the challenge of increased competition for off-patented molecules, with new entrants now appearing within 6 months, necessitating continuous innovation and novel formulations to maintain market share and profitability. They aim to launch 3-4 new active ingredients (Als) annually in the technical segment.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.